Clinical Therapeutics
September 2026
Jonathon K. Lisano, Luiza Rosa, Greg Giordano et al.
Emerging research indicates that the use of cannabis products, particularly those higher in cannabidiol (CBD), may be anxiolytic. Physical activity is another modality observed to have anxiolytic effects. Despite evidence of cannabis and physical activity being paired together, there is limited research on the possible synergistic effects of physical activity and cannabis use on reductions in...
Human Psychopharmacology: Clinical and Experimental
September 1, 2025
Renée Martin-Willett, Carillon J. Skrzynski, Angela D Bryan et al.
This study examined the effects of tetrahydrocannabinol (THC) and cannabidiol (CBD) on negative mood and drinking behaviors, and whether those effects were moderated by levels of perceived discrimination among participants who identify with a racial, ethnic, gender, or sexual identity that is underrepresented in research. Participants were either not using cannabis, using cannabis with THC, or...
Cannabis and Cannabinoid Research
February 1, 2025
Margy Y. Chen, Emily B Kramer, Laurel P Gibson et al.
Objective: Cannabis has been touted for a host of pharmacological and therapeutic effects and users commonly report reduced symptoms of physical and mental health conditions, including anxiety, depression, and chronic pain. While there is existing empirical evidence supporting these effects of cannabis use, little is known about the extent to which these effects result from pharmacological...
Cannabis and Cannabinoid Research
February 1, 2024
Laurel P Gibson, Raeghan L. Mueller, Evan A Winiger et al.
Background: The popularity of edible cannabis products continues to grow in states with legal cannabis access, but few studies have investigated the acute effects of these commercially available products. The present study sought to explore the effects of three commercially available edible products with different levels of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). Methods: A...
Experimental and Clinical Psychopharmacology
December 2023
Renée Martin-Willett, Carillon J. Skrzynski, Hollis C Karoly et al.
Highly potent cannabis concentrates are widely available and associated with affective disturbance and cannabis use disorder. Little is known about the effects of concentrated Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and their relationship to long-term affect. We explored how baseline affective symptoms (anxiety and depression) relate to acute (i.e., immediate or short-term)...
Addiction Biology
2022
Laurel P Gibson, Hollis C Karoly, Jarrod M. Ellingson et al.
Using a federally compatible, naturalistic at-home administration procedure, the present study examined the acute effects of three cannabis flower chemovars with different tetrahydrocannabinol (THC) to cannabidiol (CBD) ratios, in order to test whether chemovars with a higher CBD content produce different effects. Participants were randomly assigned to ad libitum administration of one of three...